InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-21.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Combs Andrew, Executive. Director active across 1 company, notably Prelude Therapeutics Inc. Cumulatively, 4 reports have been logged. Split: 3 buys · 0 sell. Total volume traded: €110k. Activity tracked since 13 December 2021. The latest transaction was filed on 25 March 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Combs Andrew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
100,000 shares@ US$0.692529.8% of flowCommon StockSEC:0001562180-25-002779:0
Canonical exit: 23 Jun 2025 (T+90)
3,075 shares@ US$1.151.6% of flowCommon StockSEC:0001562180-24-008565:0
Canonical exit: 20 Mar 2025 (T+90)
36,062 shares@ US$1.8935.8% of flowCommon StockSEC:0001209191-22-022524:0
4,000 shares@ US$12.1224.9% of flowCommon StockSEC:0001209191-21-069796:0
Canonical exit: 13 Mar 2022 (T+90)
4 of 4 declarations
About Combs Andrew
Andrew Combs is Executive Vice President and Head of Chemistry at Prelude Therapeutics Inc. He oversees the company's research and development initiatives, focusing on innovation in the therapeutic area.
